Neurolief

Big things are coming. 🧠 Behind the scenes info from our new CMO Dr. Owen M.

Neurolief, a leader in brain stimulation for mental health and neurological disorders, is pleased to announce the appointment of Owen Scott Muir, M.D., DFAACAP, as its fractional Chief Medical Officer (CMO). Dr. Muir brings a unique combination of expertise in psychiatry and extensive experience with FDA-regulated medical devices. His leadership will play a pivotal role in advancing Neurolief’s mission to deliver safe and effective brain stimulation therapy for patients with major depressive disorder who have not responded to traditional treatments. Dr. Muir is a dual board-certified psychiatrist in both child and general psychiatry, with expertise in managing complex mood disorders. He serves as a Clinical Assistant Professor of Medicine at the Menninger Department of Psychiatry and Behavioral Sciences, where he contributes to advancing psychiatric education and research. As the co-founder of Fermata, a neuromodulation-first medical practice, Dr. Muir has been at the forefront of integrating innovative technologies with clinical practice, driving meaningful improvements in patient outcomes. A prolific scientific author and speaker, he has also served as strategic advisor to industry.

🧠 Who is a Good Candidate for Migraine Neuromodulation Therapy? For patients struggling with chronic migraines, medication side effects, or overuse headaches (MOH), neuromodulation offers a non-invasive, drug-free alternative. But who benefits most? ✅ Frequent migraine sufferers (8+ days/month) ✅ Patients who can’t tolerate meds or want fewer side effects ✅ Those seeking to reduce reliance on painkillers ✅ Anyone looking for an at-home, FDA-cleared treatment Relivion MG is leading this revolution, delivering multi-channel neuromodulation for faster, more effective relief. For doctors, this means a clinically validated, non-pharmacological option to help patients regain control of their lives. For investors, this represents an opportunity to be part of a rapidly growing field in digital health and neuromodulation. 🔗 Learn more: https://lnkd.in/gX7dbCRy

We recently unveiled our pivotal multicenter RCT clinical study results for our upcoming Proliv™Rx brain neuromodulation therapy at the prestigious 7th Annual Neuropsychiatric Drug Summit in Boston. "Proliv™Rx offers an accessible and effective solution for patients whose depression is unresponsive to medications, many of whom have endured years of persistent symptoms. This therapy has the potential to become an essential tool in the mental health treatment landscape." - Dr. Linda Carpenter, Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University https://lnkd.in/gfAHA7dW

I am very excited about these results and the impact that this therapy will have on patients suffering from depression and not responding to first line treatments - all from the comfort of their homes and their schedules!

We are thrilled to announce the successful completion of our pivotal clinical trial for the treatment of Major Depressive Disorder! This study marks a historic milestone as the first-ever Randomized Controlled Trial (RCT) to demonstrate success in a non-pharmacological home therapy for Treatment Resistant Major Depression. The success of this pivotal trial not only demonstrates the efficacy and safety of our groundbreaking brain neuromodulation technology but also highlights its transformative potential in revolutionizing depression and mental health treatment. And as Dr. Mark George, distinguished professor of psychiatry, radiology, and neuroscience and director of the Medical University of South Carolina (MUSC) Brain Stimulation Division, said: “This is a great day for patients with depression”. https://lnkd.in/dzi67unx #MentalHealth #DepressionTreatment #Innovation #ClinicalTrial #MentalHealthRevolution#BrainNeuromodulation#

Migraine is often misunderstood, leading to misdiagnoses and inadequate treatment options. It’s time to change that. Our latest blog post is a must-read for anyone committed to advancing migraine care and innovation. Share this with your network to spread awareness and foster a more informed community. Together, we can make a significant impact on the lives of those suffering from migraines. . . . . . . . #Healthcare #Migraine #Neurology #MedicalInnovation #InvestmentOpportunities #Relivion #MedicalResearch #HealthTech #DoctorCommunity

As healthcare professionals, understanding the patient experience is crucial in evaluating new treatments. Here’s a firsthand account of what using Relivion feels like, a question frequently asked by prospective patients, from Kaylon Evans, a real Relivion user. 🔍 Why Relivion? *Non-invasive *Clinically proven *User-friendly technology We believe Relivion offers a promising avenue for #migraine relief and represents a significant #investment opportunity in #healthcare #technology.

In our latest blog post, we dive into five approaches that can help patients approach #migraine pain management, including the use of #neuromodulation technologies like Relivion MG. . . . . . . #neuroscience #migrainepain #innovation #blog https://lnkd.in/gmQpx9KX

Meet Kaylon Evans, a #migraine warrior who found relief with Relivion MG. His testimonial is a beacon of hope for those battling migraine disease. Now, with Relivion more accessible and affordable than ever, relief is within reach. Relivion® MG is indicated for the acute treatment of migraine with or without aura in patients 18 years of age or older. It is a prescription device to be self-used at home. As with any treatment, results may vary.